Premium
Daclizumab: another option for highly active relapsing‐remitting MS
Author(s) -
Gaber Tarek,
Shippen Clare
Publication year - 2017
Publication title -
progress in neurology and psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.19
H-Index - 12
eISSN - 1931-227X
pISSN - 1367-7543
DOI - 10.1002/pnp.478
Subject(s) - daclizumab , relapsing remitting , multiple sclerosis , medicine , surgery , psychiatry , transplantation , tacrolimus
Daclizumab provides clinicians with a new treatment option for patients with relapsing‐remitting multiple sclerosis. Here the authors consider its benefits compared with other multiple sclerosis drugs and its likely place in therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom